CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Head & Neck Cancers
Immunotherapy in GU Cancers
Immunotherapy in Lung Cancer
Immunotherapy in Melanoma
Mantle Cell Lymphoma
Melanoma & Skin Cancer
Oncology Nursing News
Precision Medicine in Oncology
Special Reports in Personalized Cancer Care
SELECT A TOPIC
Attend An Event
State of the Science Summit
Regional Seminar Series
OS by PS in Metastatic Pancreatic Cancer Treatment- Data From an Exploratory Subgroup Analysis
<< View More Conferences
2015 SNO Annual Meeting
Oncology Conference Multimedia
View more videos >>
Dr. Michael Lim on Toxicities of Checkpoint Inhibitors
Dr. Gilbert on Precision Medicine in Glioblastoma
Dr. Okada Discusses Immunotherapy Response Assessment in Neuro-Oncology
Oncology Conference Articles
Optimizing Precision Medicine Approaches in Glioblastoma
The deployment of precision medicine to develop safe and effective therapies to treat malignant brain tumors is an effort that poses both opportunities and challenges.
'Groundbreaking' Global Brain Cancer Trial Planned
An international coalition of experts is planning an innovative clinical trial aimed at speeding up the development of new treatments for patients with glioblastoma multiforme, putting into motion a biomarker-driven approach that has been employed in other malignancies.
Early Research Signals Potential for CAR T-Cell Therapy in EGFRvIII-Positive GBM
A pilot study of the efficacy of CAR T-cell therapy in patients with EGFRvIII-positive glioblastoma multiforme (GBM) has generated encouraging findings.
Rindopepimut Combo Continues to Show Strong OS Benefit in Relapsed GBM
Treatment with the immunotherapy rindopepimut plus bevacizumab resulted in a 47% reduction in the risk of death compared with bevacizumab and a control for patients with relapsed glioblastoma multiforme.
Promising Subgroup Data Leads to Phase III Immunotherapy Study for GBM
Findings from a subgroup of patients enrolled in a phase II study assessing the dendritic vaccine ICT-107 for patients with HLA-A2+ glioblastoma multiforme merit further exploration in a phase III study.
June Provides Insight Into Managing AEs From CAR T-Cell Therapies
Though clinical work is ongoing and early, researchers are already considering how to manage potentially fatal neurotoxicities in patients treated with chimeric antigen receptor T-cell therapy
Immune Checkpoint Inhibitors Hold Promise In Glioblastoma
There are reasons to suggest that immune checkpoint inhibitors may be successful against central nervous system tumors, including glioblastoma.
Second-Line Optune Improves Survival in GBM
The addition of Optune to chemotherapy and/or bevacizumab improved survival in patients with recurrent glioblastoma multiforme.
Testing Checkpoint Inhibitors in Brain Cancer Requires Careful AE Management
As immunotherapy begins to be studied across central nervous system tumors it becomes increasingly important for practitioners to understanding the unique adverse event profiles associated with these agents.
FDA Approvals in Pediatric ALL and PNH, Japanese Approves Pembrolizumab in 5 Indications, and More
FDA Issues Letter Regarding Safety Concerns With Paclitaxel-Coated Devices
Treatment Goals in Refractory mCRC
Controversy Adds Caution to CRISPR Editing in United States
FDA Grants Zanubrutinib Breakthrough Designation for Mantle Cell Lymphoma
Covering Every Angle of Oncology Practice. Click a cover below, to view more.
American Journal of Managed Care
Oncology Nursing News
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
Terms & Conditions
2 Clarke Drive
Cranbury, NJ 08512
Copyright OncLive 2006-2018
Intellisphere, LLC. All Rights Reserved.